Indian markets are set to open on Monday after a truncated trading week, with investors keeping an eye on major developments in banking, IT, pharma, and infrastructure sectors. Here are the key stocks that could be in focus:
1. IndusInd Bank
The Reserve Bank of India (RBI) issued a clarification on speculation regarding IndusInd Bank, stating that the bank remains well-capitalized and financially stable. As per RBI, IndusInd Bank reported a Capital Adequacy Ratio of 16.46%, a Provision Coverage Ratio of 70.20%, and a Liquidity Coverage Ratio (LCR) of 113% as of March 9, 2025, exceeding the regulatory requirement of 100%.
2. Infosys
IT services major Infosys McCamish Systems LLC has reached an agreement to settle six class action lawsuits in the United States related to a cyber incident in November 2023. Following mediation on March 13, 2025, Infosys McCamish agreed to pay $17.5 million into a settlement fund to resolve all claims.
3. Wipro
Wipro announced a realignment of its Global Business Lines (GBLs) to enhance its focus on AI, cloud, and digital transformation. The restructuring, effective from April 1, 2025, will maintain four business lines tailored to evolving client needs.
4. Brigade Enterprises
The real estate company has launched its latest residential project, Brigade Eternia, in Yelahanka, Bengaluru. Spread across 14.65 acres, the project consists of 1,124 residential units with an estimated revenue potential of ₹2,700 crore. The company also launched “Ebony at Brigade Orchards”, a premium joint venture residential project in Devanahalli, Bengaluru.
5. Zydus Lifesciences
The company announced the successful completion of a USFDA inspection at its API Unit 1 in Ankleshwar, Gujarat. The surveillance inspection from March 10 to March 14, 2025, concluded without any observations, marking a positive regulatory milestone for the firm.
6. Shilpa Medicare
Pharmaceutical firm Shilpa Pharma Lifesciences Ltd, a wholly-owned subsidiary, cleared a USFDA inspection at its Unit-2 facility in Raichur with zero observations. The inspection concluded without Form 483 being issued, marking the second consecutive clean inspection at the site.
7. JB Chemicals
The company’s API manufacturing facility (D9) in Panoli, Gujarat, successfully cleared a USFDA inspection from March 10 to March 13, 2025, without any Form 483 observations.
8. TCS
India’s largest IT services firm, TCS, has appointed Sudeep Kunnumal as Chief Human Resources Officer (CHRO) Designate, effective March 14, 2025. He will take over as CHRO after Milind Lakkad’s superannuation.
9. Power Grid
The state-owned Power Grid Corporation of India Ltd approved an investment of ₹341.57 crore for two transmission projects. The projects, scheduled for completion by July 14, 2026, include:
- Transmission scheme for evacuation of power from Ratle HEP (850 MW) & Kiru HEP (624 MW) worth ₹218.55 crore.
10. Alkem Laboratories
Pharmaceutical company Alkem Laboratories announced that the USFDA conducted a Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra, from March 10 to March 13, 2025.
11. Ceigall India
Infrastructure firm Ceigall India received a Letter of Award (LOA) from NHAI for the development of a six-lane greenfield southern Ludhiana bypass under the Hybrid Annuity Mode (HAM). The ₹2,700 crore project is part of the Ludhiana-Ajmer Economic Corridor in Punjab.
With key US Federal Reserve FOMC meeting on March 18-19, along with ongoing institutional investor activity, market sentiment will be closely tracked. Investors should watch for developments in IT, pharma, banking, and infrastructure sectors as these key stocks react to fresh updates.
